Talk:Adrenocorticotropic hormone (medication)

Latest comment: 5 years ago by RMCD bot in topic Move discussion in progress

JAMA Internal Medicine 2017

edit

This article discusses the high cost and lack of evidence for many indications.

http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2653010 Trends and Characteristics of US Medicare Spending on Repository Corticotropin Daniel M. Hartung, PharmD, MPH; Kirbee Johnston, MPH; Shelby Van Leuven; et al. JAMA Intern Med. September 11, 2017. doi:10.1001/jamainternmed.2017.3631

This study uses Medicare Drug Spending Dashboard data to estimate the cost of repository corticotropin to the Medicare program and assess its within-specialty prescribing patterns.

Repository corticotropin (rACTH) injection (H. P. Acthar gel; Mallinckrodt Pharmaceuticals) has been under intense scrutiny for its very high cost.1,2 Because rACTH is approved for a variety of immunologic conditions prevalent in the US Medicare population, prescriptions for rACTH may have a significant financial impact on Medicare expenditures. The objectives of this study were to (1) estimate the cost of rACTH to the Medicare program, and (2) assess the within-specialty prescribing patterns for this medication.

--Nbauman (talk) 04:30, 12 September 2017 (UTC)Reply

Move discussion in progress

edit

There is a move discussion in progress on Talk:Lithium (medication) which affects this page. Please participate on that page and not in this talk page section. Thank you. —RMCD bot 23:15, 28 January 2019 (UTC)Reply